A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf.
ADAM15 expression associates with survival in triple negative breast cancer
[post]
2021
unpublished
Preserved Fulltext
We mined published microarray data (1) to understand the most significant gene expression differences in the tumors of triple negative breast cancer patients based on survival following treatment: dead or alive. We observed significant transcriptome-wide differential expression of ADAM metallopeptidase domain 15, encoded by ADAM15 when comparing the primary tumors of triple negative breast cancer patients dead or alive. ADAM15 may be of relevance as a biomarker or as a molecule of interest in
doi:10.31219/osf.io/nhfa4
fatcat:j765tkabqnb3bakhorztwttd2u